Upstream Bio UPB
Upstream Bio reports $41.19 million net loss for Q3 2026
Upstream Bio (UPB) filed a 10-Q with the SEC on Nov 10, 2026, 7:11 am ET. Source: the filing on SEC EDGAR.
Quarterly report, 3 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001193125-26-454422
- Revenue: $395,000 for the three months ended Sep 30, 2026
- Net loss: $41.19 million for the three months ended Sep 30, 2026
- Cash and equivalents: $47.42 million at Sep 30, 2026
- Diluted EPS: -$0.75 for the three months ended Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
3 new risk factors · 2 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $395K | $773K | −49% |
| Operating income and margin | −$43.38M · -10982% | −$42.37M · -5481% | −2.4%, margin −5501 pts |
| Net income | −$41.19M | −$39.7M | −3.8% |
| Operating cash flow | −$54.23M | −$35.62M | −52% |
| Cash | $47.42M | $79.4M | −40% |
New risk factors (3)
- Additionally, in the EEA, the NIS 2 Directive ("NIS 2") expands cybersecurity requirements to certain medium-sized and large organizations in specified sectors, including certain healthcare and life sciences organizations engaged in the research and development of medicinal products. NIS 2 imposes enhanced…
- 2025, or if global health concerns, funding shortages or staffing limitations hinder or prevent the FDA, the SEC or other regulatory authorities from conducting their regulatory inspections, reviews or other regulatory activities, including formal or informal interactions with product developers, it could…
- In December 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs: the Global Benchmark for Efficient Drug Pricing Model ("GLOBE") for Medicare Part B and the Guarding U.S. Medicare Against Rising Drug Costs ("GUARD") model for Medicare… +1 more paragraph
Removed risk factors (2)
- Additionally in the EEA, the NIS 2 Directive ("NIS 2") is replacing the cybersecurity legal framework under the current NIS framework, aiming to ensure a high level of cybersecurity in the region. NIS 2 brings new medium and large organizations providing services in the EEA within scope of the legal framework. It…
- Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. The general approach for FDA approval of a new drug has generally been dispositive data from two or more adequate and well-controlled clinical trials of the product candidate in…